Pixantrone monotherapy is recommended as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma if:
- they have previously been treated with rituximab and
- they are having third- or fourth-line treatment.
What does this mean for me?
If you have non-Hodgkin’s B-cell lymphoma, and your doctor thinks that pixantrone is the right treatment, you should be able to have it on the NHS.
Pixantrone should be available on the NHS within 3 months of the guidance being issued. If you are not eligible for treatment on the NHS as described above, you should be able to continue having pixantrone until you and your doctor decide it is the right time to stop.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.